Vendor consolidation accelerates operational design in clinical trials

Vendor consolidation is emerging as more than a procurement choice in clinical trials; it is increasingly a question of operational design. When sponsors and CROs split work across too many suppliers, the result can be a chain of hand-offs that slows production, complicates version control and leaves internal teams acting as the glue between disconnected processes.

That risk is amplified in a sector where execution is tightly linked. Study materials, translation, printing, kitt...

ing, shipping and country roll-out often have to move in step, and a change in one area can trigger a cascade elsewhere. According to Imperial Clinical Research Services, consolidation delivers the most value when it creates genuine integration across those functions, rather than simply reducing the supplier count on paper.

The appeal is straightforward. Fewer vendors can mean clearer accountability, quicker decisions and less time spent reconciling mismatched timelines. It can also reduce the hidden administrative load that accumulates when study teams are forced to coordinate approvals, chase status updates and correct errors created by fragmented workflows.

Industry commentary suggests the problem is widespread. One analysis cited in the related material says more than 85% of global Phase II to IV trials involve at least three external vendors, underscoring how common multi-supplier models have become. Another warns that fragmented supply chains can contribute to delays of three to six months and cost overruns of 15% to 25%, particularly in smaller biotech programmes that lack deep internal resources.

The core issue is not simply the number of vendors, but how well they are connected. An integrated model can bring writing, design, linguistics, production and logistics into a shared workflow, allowing teams to anticipate issues such as text expansion, layout changes and regional formatting requirements before materials reach final proofing. That, in turn, can help avoid rework when protocol amendments or local adaptations arise.

By contrast, fragmented execution often pushes problems downstream. Files may move to a translation supplier before that team is ready, approved content may come back too long for the design template, and shipping plans may stall while different vendors wait on each other. In those situations, sponsors and CROs are left to manage the interfaces themselves, often spending more time coordinating than actually advancing the study.

Protocol amendments make this even more consequential. Tufts CSDD benchmarks, as cited in the source material, indicate that most protocols require at least one substantial amendment, with the frequency rising in later-stage Phase III work. Because changes often affect materials, supply plans, translation and distribution at once, a fragmented vendor model can turn a routine update into a slow, uneven implementation across countries and sites.

There are also regulatory stakes. FDA rules require sponsors to submit protocol amendments for new protocols and significant changes, and work may proceed once the amendment has been filed with the agency and approved by the relevant institutional review board. That makes the speed and consistency of downstream execution all the more important.

A better model, Imperial argues, is one built around shared ownership and unified change control. In practice, that means one lead coordinating related services, one view of timelines and inventory, and one process for approvals and release. The same logic is being echoed in wider industry discussions about unified trial systems, where disconnected platforms and manual reconciliation are blamed for slower issue resolution and unnecessary duplication.

The business case is not only about speed. Consolidation can also strengthen commercial leverage, reduce administrative overhead and make large-scale global roll-outs easier to manage. For sponsors weighing whether to consolidate, the key test is not whether every service sits under one roof, but whether the operating model keeps interdependent tasks aligned as the study evolves.

That distinction matters. Some programmes need broad coordination across materials, translation, ancillary supplies and logistics. Others may only need focused support in a narrower area. But as trials become more complex, the cost of fragmentation is often measured not just in delays, but in the cumulative burden placed on internal teams trying to keep everything in sync.

Source: Noah Wire Services